This Bull Bets on 533% Upside Potential for Advaxis, Inc. (ADXS) Shares

Cantor’s Mara Goldstein acknowledges shares have hit some challenges in the latest months, but believes ultimately the company’s programs carry “undiminished” value.

Stock Update (NASDAQ:ADXS): Advaxis, Inc. Abstracts Set for Presentation at 32nd Annual Society for Immunotherapy Cancer Meeting

Advaxis, Inc. (NASDAQ:ADXS) announced two abstracts were selected for presentation at the 32nd annual Society for Immunotherapy of Cancer (SITC) meeting.

Just How Frustrated Should Investors Be with Advaxis, Inc. (ADXS)? H.C. Wainwright Remains Bullish

Analyst defends ADXS’ new “astute” clinical development strategy to re-focus on leading product assets.

Company Update (NASDAQ:ADXS): Advaxis, Inc. and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy

Advaxis, Inc. (NASDAQ:ADXS) and SELLAS Life Sciences Group announced that Advaxis has granted SELLAS a license to develop a novel cancer immunotherapy agent …

Stock Update (NASDAQ:ADXS): Advaxis, Inc. Issues Business Outlook for 2017

Advaxis, Inc. (NASDAQ:ADXS) issued its 2017 business outlook to provide an overview of anticipated events and key milestones for the coming year, as …

Stock Update (NASDAQ:ADXS): Discussion on Advaxis, Inc.’s ADXS-NEO, ADXS-HOT Programs Held During the International Congress on Immunotherapies in Cancer

Advaxis, Inc. (NASDAQ:ADXS) announced that the company’s proprietary bacterial vector system, its Lm Technology™, was the focal point of a luncheon during the …

Company Update (NASDAQ:ADXS): Advaxis, Inc. Announces GOG-0265 12-month Overall Survival Rate of 37.5% in Stage 2

Advaxis, Inc. (NASDAQ:ADXS) announced topline results from the early closure of stage 2 of the Phase 2 GOG-0265 trial, conducted by the Gynecologic Oncology …

Stock Update (NASDAQ:ADXS): Advaxis, Inc. Initiates Combination Portion of Phase 1/2 Study with Merck

Advaxis, Inc. (NASDAQ:ADXS) announced the commencement of Part B of the KEYNOTE-046 clinical trial evaluating Advaxis’ Lmimmunotherapy candidate, ADXS-PSA, in combination with KEYTRUDA (pembrolizumab) …

Company Update (NASDAQ:ADXS): Advaxis, Inc. to Receive $2.5M through the New Jersey Economic Development Authority NOL Program

Advaxis, Inc. (NASDAQ:ADXS) has received preliminary approval for a $2.

Company Update (NASDAQ:ADXS): Advaxis, Inc. Unveils State-of-the-art Manufacturing Facility, Laboratory to Produce and Develop Novel Immuno-Oncology Therapeutics

Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, welcomed New Jersey Governor Christopher J.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts